Food allergies can be deadly but also costly for those concerned
The latest treatment for peanut allergy can cost around $10,000 a year and was supposed to be a pharma blockbuster. What went wrong?
Source: swissinfo.ch
Page 4 - Greg Behar News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Greg Behar. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Greg Behar Today - Breaking & Trending Today
Seres Therapeutics and Nestlé Health Science Announce U.S. Commercial Availability of VOWST™, the First and Only FDA-Approved Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection
– VOWST is now available by prescription in the U.S. for adult patients following antibiotic treatment for recurrent CDI – – VOWST Voyage™ Support Program to help reduce... | June 5, 2023
Source: marketscreener.com
FDA approves Cambridge firm's intestinal drug made from microorganisms in the gut
It’s the first pill to treat a serious and sometimes fatal bacterial condition.
Source: bostonglobe.com
Nestle to sell peanut-allergy treatment bought 2 years ago
Nestle put its Palforzia peanut-allergy treatment up for sale only two years after buying it, as Chief Executive Officer Mark Schneider reverses course on one of his biggest acquisitions beyond the Swiss company's traditional food and beverage operations.
Source: arkansasonline.com
ChromaDex and Nestlé Health Science Announce New Niagen Commercial Supply Agreement and $5 Million Investment
11.10.2022 - ChromaDex Corp. (NASDAQ:CDXC) (“the Company” or “ChromaDex”) a global bioscience company dedicated to healthy aging, announced today a new long term commercial license and supply agreement with Nestlé Health Science, a global leader in science-based ... Seite 1
Source: wallstreet-online.de